Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.

What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Jaksot(36)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Maalis 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Joulu 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Marras 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Syys 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Touko 202521min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Huhti 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Huhti 202521min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
adhd-podi
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-rahamania
jari-sarasvuo-podcast
psykologia
rss-valo-minussa-2
rss-tietoinen-yhteys-podcast-2
kesken
rss-arkea-ja-aurinkoa-podcast-espanjasta
rss-narsisti
rss-vapaudu-voimaasi
rahapuhetta
filocast-filosofian-perusteet
ihminen-tavattavissa-tommy-hellsten-instituutti
kehossa
rss-psykalab